Maxillofacial Plastic and Reconstructive Surgery

Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지

EFFICIENCY OF SERUM TUMOR MARKERS ORAL SQUAMOUS CELL CARCINOMA PATIENTS

구강 편평세포암종 환자의 혈청 종양표지자의 유용성

  • Bhang, Dae-Yeon (Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University) ;
  • Kim, Chul-Hwan (Department of Oral and Maxillofacial Surgery, College of Dentistry, Dankook University)
  • 방대연 (단국대학교 치과대학 구강악안면외과학교실) ;
  • 김철환 (단국대학교 치과대학 구강악안면외과학교실)
  • Published : 2009.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Recently, the role of serum tumor marker has been studied for an important issue on diagnosing and treating tumors in the head and neck region because tests using tumor markers need relatively simple procedures and are acceptable to patients, compared with other test methods. Tumor marker tests were performed on patients with squamous cell carcinoma, which were known to have the highest prevalence among tumors in the head and neck region. Association between each tumor marker, and diagnosis and prognosis of tumors was assessed. Materials and methods: Tumor marker tests were carried out on 31 patients who visited Oral and Maxillofacial Surgery Department in Dankook University Dental Hospital between January 2003 and August 2008 and who were diagnosed as primary oral squamous cell carcinoma through out histopathologic diagnosis. Blood sample from these patients was performed to measure tumor markers using nuclear medicine diagnostic equipment. Measured entries were as follows: PSA(prostate-specific antibody), SCCAg( Squamous Cell Carcinoma Related Antigen), CA 19-9(Cancer Antigen 19-9), Ferritin, $\alpha$- FP(Alpha-Fetoprotein), Cyfra 21-1, CA125 (Cancer Antigen 125) and p53. Results: Analyses on each tumor marker indicated that squamous cell carcinoma in the head and neck region had statistically significant correlation with p53, SCC-Ag(TA-4), Cyfra 21-1 and Ferritin. p53 demonstrated the highest sensitivity. Especially, 4 cases among 18 cases which Ferritin was measured exhibited metastasis. In all those 4 cases, Ferritin values were higher than the standards (15 - 332ng/ml). Therefore, Ferritin is considered to have a close relation with metastasis of squamous cell carcinoma. Conclusion: This study shows that tumor marker tests are more useful in evaluating progression and prognosis of tumors rather than in diagnosing them. Particularly, serum Ferritin is considered to be beneficial in assessing metastasis of squamous cell carcinoma in the head and neck region and in developing treatment plans based on the assessment.

Keywords

References

  1. Ogawa T, Tsurusako Y, Kimura N et al: Comparison of tomur markers in patients with squamous cell carcinoma of Head and Neck. Acta Otolaryngol Suppl 540: 72-76, 1999 https://doi.org/10.1080/00016489950181972
  2. Kurokawa H, Tsuru S, Okada M et al: Evaluation of tumor markers in patients with squamous cell carcinoma in the oral cavity. Int J Oral Maxillofac Surg 22: 35-38, 1993 https://doi.org/10.1016/S0901-5027(05)80353-4
  3. Kelly WM: Tumor markers: a review. Radiography 54: 14-27, 1988
  4. Ruoslahti E, Seppala M: Studies of carcinofetal proteins: physical and chemical properties of human alpha-fetoprotein. Int J Cancer 7: 218-225, 1971 https://doi.org/10.1002/ijc.2910070205
  5. Nakata B, Ogawa Y, Ishikawa T et al: Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89: 1285-90, 2000 https://doi.org/10.1002/1097-0142(20000915)89:6<1285::AID-CNCR13>3.0.CO;2-G
  6. Hashimoto T, Matsubara F: The need for primary quality control of commercially available immunoassay kits. Journal of Clinical Pathology 44 : 165-167, 1991 https://doi.org/10.1136/jcp.44.2.165
  7. Catalona WJ, Smith DS, Ratliff TL et al : Measurement of prostate-specific antigen as a screening test for prostate cancer. New Engl J Med 324 : 1156-61, 1991 https://doi.org/10.1056/NEJM199104253241702
  8. Cazzola M, Arosio P, Bellotti V et al: Immunological Reactivity of Serum Ferritin in Patients with Malignancy. Tumori 71: 547-554, 1985
  9. Milman N, Kirchhoff M, J¨orgensen T: Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Ann Hematol 65: 96-102, 1992 https://doi.org/10.1007/BF01698138
  10. DelVillano B, Brennan S, Brock P et al: Radioim-munometric assay for a monoclonal antibody - Defined tumor marker, CA 19-9. Clin Chem 29; 549, 1983
  11. Kato H, Torigoe T : Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40: 1621, 1977 https://doi.org/10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I
  12. Yamazawa K, Shimada H, Hirai M et al : Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. American J of Obstetrics and Gynecology 197(5) , p.505.e1-505.e7, 2007 https://doi.org/10.1016/j.ajog.2007.04.033
  13. Lucinei RO, Alfredo RS, Sergio Z: Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 36: 191-197, 2007 https://doi.org/10.1111/j.1600-0714.2007.00517.x
  14. Sauter ER, Ridge JA, Gordon J et al: p53 overexpression correlates with increased survival in patients with squamous carcinoma of th tongue base. Am J Surg 164: 651-653, 1992 https://doi.org/10.1016/S0002-9610(05)80727-5
  15. Nylander K, Dabelsteen E, Hall PA: The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 29: 413-425, 2000 https://doi.org/10.1034/j.1600-0714.2000.290901.x
  16. Khademi B, Shirazi FM, Vasei M et al: The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 184: 223-230, 2002 https://doi.org/10.1016/S0304-3835(02)00242-2
  17. Yen TC, Lin WY, Kao CH et al: A study of a new tumour marker, Cyfra 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci 23: 82-86, 1998 https://doi.org/10.1046/j.1365-2273.1998.00101.x
  18. Nagler RM, Barak M, Peled M et al: Early diagnosis and treatment monitoring roles of tumour markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 85: 1018-1025, 1999 https://doi.org/10.1002/(SICI)1097-0142(19990301)85:5<1018::AID-CNCR2>3.0.CO;2-R
  19. Ceruse P, Rabilloud M, Charrie A et al: Study of Cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 114: 768-776, 2005
  20. Doweck I, Barak M, Uri N et al: The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83: 1696-1701, 2000 https://doi.org/10.1054/bjoc.2000.1502
  21. Banal A, Hacene K, Berthelot-Ruff E et al: Comparison of Cyfra 21-1 and SCC assays in head and neck tumors. Tumour Biol 22: 27-35, 2001 https://doi.org/10.1159/000030152
  22. Zhong LP, Zhu HG, Zhang CP et al : Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg 36: 230-234, 2007 https://doi.org/10.1016/j.ijom.2006.06.016
  23. Doweck I, Barak M, Greenberg E et al : Cyfra 21-1: a new potential marker for squamous cell carcinoma of head neck Arch Otolaryngol Head Neck Surg 121: 177-181, 1995 https://doi.org/10.1001/archotol.1995.01890020039009
  24. Niklinski J, Furman M, Chyczewski L et al: Evaluation of Cyfra 21-1 as a new marker for non-small cell lung cancer. Eur J Cancer Prev 3: 227-230, 1994 https://doi.org/10.1097/00008469-199403000-00009
  25. Clasen B, Pere P, Senekowitsch R et al: Tumorzelltod im spoegel der SCC-antigentiter? Laryngo-Rhino-Otol 70: 251-254, 1991
  26. Molina R, Torres MD, Moragas M et al : Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res 15: 479-484, 1995
  27. Michael K, Jurgen H, Cinatanze K et al : Relevance of SCC-Ag, CEA, CA 19-9 and CA 125 for diagnosis and follow-up in oral cancer. J of Cranio-Maxillofacial Surgery 26 : 243-248, 1998 https://doi.org/10.1016/S1010-5182(98)80020-6
  28. Johnson J, Wagner R, Eibling D : Radioimmunoassay for SCC antigen in the diagnosis of squamous cell carcinoma of the head and neck: A preliminary report. Princeton: Excerpta Medica 112-123, 1987
  29. Adelman TG, Drysdale JW : Synthesis of ferritin subunits by free and membrane bound ribosomes, New York, Grune & Stratton, 1977, p.49-65
  30. Watanabe N, Niitsu YU, Koseki J et al : A mechanism for evaluation of serum ferritin in malignancy: A study of nude micewith innoculated human tumors. J Clin Exp Med 110: 686-688, 1979
  31. M. Prutki, M. Poljak-Blazi, M. Jakopovic et al: Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Letters 238: 188-196, 2006 https://doi.org/10.1016/j.canlet.2005.07.001
  32. Rikushi M, Masao Y, Kotoko N et al : Clinical evaluation of serum ferritin to iron ratio in malignant diseases. Eur J Nucl Med 6: 331-336, 1981 https://doi.org/10.1007/BF00262528
  33. Nakano S, Kumada T, Kitamura K et al: Clinical evaluation of serum ferritin in the diagnosis of liver disease. Jpn J Gastroenerol 76: 1306-1313, 1979
  34. Arosio p, Yokota M, Drysdale JW : Structural and immunological relationships of isoferritins in normal and malignant cells. Cancer Res 36: 1735-1739, 1976
  35. P.I. Hsu, N.H. Chow, X.Z. Lin : Prognostic significance of ferritin expression in colorectal adenocarcinoma. Anticancer Rec 5: 1087-1093, 1995
  36. Prieto J, Barry M, Sherlock S : Serrum ferritin in patients with iron overload and with acute and chronic liver disease. Gastroenterology 68: 525-533, 1975
  37. Niitsu Y, Koeski J, Watanabe N et al : Diagnosis of latent iron deficiency by serum ferritin concentration. Jpn J Clin Hematol 20: 1-7, 1979
  38. Parkin DM, Bray F, Ferlay J et al: Global cancer statistics. CA Cancer J Clin 55 : 74-108, 2005 https://doi.org/10.3322/canjclin.55.2.74
  39. Neville BW, Day YA: Oral cancer and precancerous lesions. CA Cancer J Clin 52: 195-215, 2002 https://doi.org/10.3322/canjclin.52.4.195